258 related articles for article (PubMed ID: 19285001)
1. Conformational detection of prion protein with biarsenical labeling and FlAsH fluorescence.
Coleman BM; Nisbet RM; Han S; Cappai R; Hatters DM; Hill AF
Biochem Biophys Res Commun; 2009 Mar; 380(3):564-8. PubMed ID: 19285001
[TBL] [Abstract][Full Text] [Related]
2. Preventing misfolding of the prion protein by trimethylamine N-oxide.
Bennion BJ; DeMarco ML; Daggett V
Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
[TBL] [Abstract][Full Text] [Related]
3. Copper induces increased beta-sheet content in the scrapie-susceptible ovine prion protein PrPVRQ compared with the resistant allelic variant PrPARR.
Wong E; Thackray AM; Bujdoso R
Biochem J; 2004 May; 380(Pt 1):273-82. PubMed ID: 14969585
[TBL] [Abstract][Full Text] [Related]
4. The elusive intermediate on the folding pathway of the prion protein.
Jenkins DC; Sylvester ID; Pinheiro TJ
FEBS J; 2008 Mar; 275(6):1323-35. PubMed ID: 18279390
[TBL] [Abstract][Full Text] [Related]
5. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization.
Kazlauskaite J; Sanghera N; Sylvester I; Vénien-Bryan C; Pinheiro TJ
Biochemistry; 2003 Mar; 42(11):3295-304. PubMed ID: 12641461
[TBL] [Abstract][Full Text] [Related]
6. Assembly of natural and recombinant prion protein into fibrils.
Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
[TBL] [Abstract][Full Text] [Related]
7. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations.
Kaimann T; Metzger S; Kuhlmann K; Brandt B; Birkmann E; Höltje HD; Riesner D
J Mol Biol; 2008 Feb; 376(2):582-96. PubMed ID: 18158160
[TBL] [Abstract][Full Text] [Related]
8. [Molecular bases of prion diseases].
Rać M; Rać M
Ann Acad Med Stetin; 2006; 52(3):5-13. PubMed ID: 17385343
[TBL] [Abstract][Full Text] [Related]
9. Tetracysteine-tagged prion protein allows discrimination between the native and converted forms.
Gaspersic J; Hafner-Bratkovic I; Stephan M; Veranic P; Bencina M; Vorberg I; Jerala R
FEBS J; 2010 May; 277(9):2038-50. PubMed ID: 20345906
[TBL] [Abstract][Full Text] [Related]
10. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
[TBL] [Abstract][Full Text] [Related]
11. Alkylating antitumor drug mechlorethamine conceals a structured PrP domain and inhibits in vitro prion amplification.
Zhou X; Bi H; Wong J; Shimoji M; Wang Y; Yuan J; Xiao X; Wang GX; Zou WQ
J Toxicol Environ Health A; 2011; 74(22-24):1493-503. PubMed ID: 22043910
[TBL] [Abstract][Full Text] [Related]
12. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form.
Jansen K; Schäfer O; Birkmann E; Post K; Serban H; Prusiner SB; Riesner D
Biol Chem; 2001 Apr; 382(4):683-91. PubMed ID: 11405232
[TBL] [Abstract][Full Text] [Related]
13. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
Sasaki K; Minaki H; Iwaki T
J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
[TBL] [Abstract][Full Text] [Related]
14. Analysis of PrP conformation using circular dichroism.
Han S; Hill AF
Methods Mol Biol; 2008; 459():145-59. PubMed ID: 18576154
[TBL] [Abstract][Full Text] [Related]
15. Monitoring prion protein stability by NMR.
Julien O; Graether SP; Sykes BD
J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
[TBL] [Abstract][Full Text] [Related]
16. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
Leliveld SR; Stitz L; Korth C
Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
[TBL] [Abstract][Full Text] [Related]
17. Concealment of epitope by reduction and alkylation in prion protein.
Yuan J; Kinter M; McGeehan J; Perry G; Kneale G; Gambetti P; Zou WQ
Biochem Biophys Res Commun; 2005 Jan; 326(3):652-9. PubMed ID: 15596149
[TBL] [Abstract][Full Text] [Related]
18. [Neurodegenerative conformational disease and its molecular bases].
Li WW; Cai DF; Ren HM
Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
[TBL] [Abstract][Full Text] [Related]
19. Chaperonin-mediated de novo generation of prion protein aggregates.
Stöckel J; Hartl FU
J Mol Biol; 2001 Nov; 313(4):861-72. PubMed ID: 11697909
[TBL] [Abstract][Full Text] [Related]
20. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
